PD59-04 APPLICATION OF THE KEYNOTE-564 TRIAL RESULTS TO REAL LIFE POPULATION: WHICH PATIENTS WITH ADVANCED KIDNEY CANCER SHOULD RECEIVE ADJUVANT PEMBROLIZUMAB

Authors :: Giuseppe Fallara
Giuseppe Rosiello
Daniele Raggi
Laura Marandino
Greta Malena
Giuseppe Basile
Gianmarco Colandrea
Daniele Cignoli
Federico Belladelli
Giacomo Musso
Francesco Cei
Roberto Bertini
Alberto Briganti
Andrea Salonia
Francesco Montorsi
Alessandro Larcher
Andrea Necchi
Umberto Capitanio
Source :: Journal of Urology. 207
Publication Year :: 2022
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2022.

Tools